









Drug Legislation Passed in 2016 and 2017

State	Target of Legislation			
	Manufacturer	PBMs	Pharmacy	Government
CA	Price Transparency			
СТ		Price Transparency		
DE		MAC Transparency		
FL			Price Transparency; study	
GA		Price Transparency		
HI		PBM Registration		
IL				Volume Based Purchasing
LA	WAC Transparency			Policy Study
MA	Price Transparency			
MD	Price Gouging		Biologics	
ME		Price Transparency		
MI	Rx Discounts			
MN			Generic Substitution	
MT				Policy Study
NC		Cost Sharing	Price Transparency	
NH		Pharmacy licensing; MAC Transparency		
NJ		Health Plan Transparency		PBM Transparency
NV	Drug Type Transparency	Drug Type Transparency	Rx Donation Programs	
NY			Biologics	Medicaid Budget
RI		Price Transparency		
SC		MAC Transparency		
TN			Rx Donation Programs	
TX				Health Benefit Plans
VT	WAC Transparency			
WA	Price Transparency		Generic Substitution	
WY		PBM Registration	Generic Substitution	

Key **Generics**

Brand

Both

Broad

Notes: This table highlights state legislation that addresses drug spending passed in 2016 and 2017. WAC stands for wholesale acquisition cost and MAC stands for maximum allowable cost. For more background on this topic, see: http://www.healthcarevaluehub.org/cost-and-quality-problems/browse-cost-driverquality-issue/prescription-drug-costs/ and for more resources, see: http://www.healthcarevaluehub.org/events/ high-drug-spending/

Source: Data was taken from the NASHP 2016 & 2017 RX legislation tracker and cross checked with the 2017 Yale Law School's Global Health Justice Partnership Policy Paper: Curbing Unfair Drug Prices - A Primer for States (2017).